Nursing & Health

Permanent URI for this collectionhttps://research.avondale.edu.au/handle/123456789/457

Browse

Search Results

  • Item
    Testofen® (Fenugreek extract) Increases Strength and Muscle Mass Compared to Placebo in Response to Calisthenics: A Randomized Control Trial
    (2020-06-25) Grant, Ross; Mallard, Alistair R.; Rao, Amanda J.

    This randomised, placebo controlled, double‐blind study aimed to examine changes in muscular strength and endurance, body composition, functional threshold power, and sex hormones in response to an 8‐week calisthenic programme with daily supplementation with Testofen® (Fenugreek extract) or a placebo. A total of 138 male participants (25‐47yrs) were enrolled and randomized to three equal groups: 600 mg Testofen®/day, 300 mg Testofen®/day or placebo. Muscle strength and endurance, functional threshold power, body composition, and sex hormones were measured at baseline, weeks 4 and 8. Participants completed a whole‐body calisthenic programme three times a week. All groups improved their maximal leg press from baseline to 8 weeks, however, both Testofen® treated groups improved more than placebo (P < .05). The 600 mg group showed decreases in body mass of 1.2 kg, −1.4% body fat and an increase in lean mass (1.8%) at 8 weeks. The 600 mg group also demonstrated an increase in testosterone concentration from baseline to 8 weeks. This study indicates that Testofen® may be an effective ergogenic aid for individuals wanting to rapidly improve their exercise performance capabilities and body composition above and beyond that of calisthenic exercise alone.

  • Item
    The Effect of Trigonella foenum‐graecum Extract on Prostate‐specific Antigen, and Prostate Function in Otherwise Healthy men with Benign Prostate Hyperplasia
    (2020-03-04) Grant, Ross; Rao, Amanda

    The aim of this trial was to evaluate the effect of a standardised Trigonella foenum‐graecum (Fenugreek) extract on the symptoms of benign prostate hyperplasia (BPH) using a double‐blind randomised placebo controlled design. The study recruited 100 healthy males aged between 45 and 80 years with symptoms of BPH who recorded a minimum score of eight on the International Prostate Symptom Score. Participants were randomised to an oral dose of either 600mg Trigonella foenum‐graceum per day or placebo for 12 weeks. The primary outcome measure was the International Prostate Symptom Score total and subdomain scores. The secondary outcomes were serum levels of the hormones (testosterone, free testosterone, and sex hormone binding globulin) prostate‐specific antigen, and safety markers. The results indicated that Trigonella foenum‐graceum did not have an effect on improving the symptoms of BPH. Hormone levels, safety markers, and prostate‐specific antigen remained unchanged and within normal limits after 12 weeks, which adds to the safety profile of this specialised extract.